Projects per year
Personal profile
Areas of Expertise
Antibiotic Resistance in Bacteria, 'Hospital Superbugs', Response to COVID Pandemic, Enterobacter Infections, Antibiotic Resistance, Microbiology, Bacteria, Antimicrobial Agents
Video: BSAC Spring Conference 2018 - Day2 - Professor David Livermore
Academic Background
1983 PhD, Medical Microbiology, University of London. Thesis: Resistance mechanisms of Pseudomonas aeruginosa to ?-lactam antibiotics.
2003 State-Registered Clinical Scientist, Health Professions Council (CS1358).
Biography
David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997, when he joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011, he became Professor of Medical Microbiology at UEA, but with 30% of this time supplied back to Public Health England as its Lead on Antibiotic Resistance.
Prof Livermore has broad interests on the evolution and dissemination of antibiotic resistance and its relationship to antibiotic prescribing. Beta-Lactamases are a particular interest, with recent work on the proliferation of ‘CTX-M’ extended-spectrum enzymes and carbapenemases, particularly NDM-1, which received extensive media coverage in 2010.
He sits on the British Society for Antimicrobial Chemotherapy working parties on resistance surveillance, multi-resistant pathogens and susceptibility testing and its Antibiotic Action advisory board, also on the Society for General Microbiology working group on sexually transmitted infections. He is also a member of the UK Government’s Antimicrobial Resistance and Healthcare Associated Infections Advisory Committee and has contributed extensively to the Chief Medical Offer for England’s Annual Report for 2011. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy and Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.
Outside of work, he is a keen walker, has walked the perimeter of Norfolk and almost half the English Coastline.
Career
9/78 to 6/80 QC Microbiology Devt., Wellcome Foundation, Dartford, Kent
6/80 to 8/97 Department of Medical Microbiology, London Hospital Medical College
6/80-11/83 Research Assistant
11/83-2/87 Postdoctoral Fellow (Wellcome Trust)
11/85-5/86 Secondment, Lecturer, University of Hong Kong
2/87-12/94 Lecturer in Medical Microbiology
12/94-8/97 Senior Lecturer in Medical Microbiology
9/97-9/00 Hon Senior Lecturer
9/98-10/11 Public Health England (formerly HPA), Microbiology Services
9/97-9/98 Head, Antibiotic Reference Unit, Colindale
9/98-date Director, Antibiotic Resistance Monitoring & Reference
Laboratory, Colindale
10/11-date Professor of Medical Microbiology, University of East Anglia (primary employer, `70% time, with 30% of this subcontracted to Public Health England )
Lead on Antibiotic Resistance, Public Health England Microbiology Services, Colindale
Visiting Professor, King Saud University, Riyadh, Saudi Arabia
Honorary Professor of Medical Microbiology, Queen Mary University, London
Consultant on Antibiotic Resistance – advisory work for numerous diagnostic and pharmaceutical companies and potential investors
Key Research Interests
My early research centred on ?-lactamases, and I showed how an apparently weak activity could protect a bacterium if the enzyme had high affinity and the ?-lactam permeated only slowly. This led to showing that models describing the interplay of ?-lactamase and permeability were adequate for Escherichia coli but not Pseudomonas aeruginosa, and I contributed to work revealing that this inadequacy was because P. aeruginosa also effluxes ?-lactams. Other early work explored the induction of AmpC ?-lactamases and the selection of AmpC-derepressed mutants from AmpC-inducible populations of Enterobacter and P. aeruginosa, showing selection to be the more important factor. I have been responsible for describing and investigating the properties of many new ?-lactamases, including those conferring resistance to carbapenems – the last reserve ?-lactams against many otherwise multiresistant bacteria.
My work increasingly spread from the mechanisms of resistance to its epidemiology. At the UK Health Protection Agency (Public Health England) I led groups that demonstrated the dramatic rises in MRSA in the late 1990s, ciprofloxacin-resistant gonococci around 2002-3, carbapenemase-resistant Acinetobacter spp. and cephalosporin-resistant E. coli from around 2003 and the recent rise in carbapenemases, partly linked to the repeated import of strains with NDM-1 enzyme via patients previously hospitalised in the Indian subcontinent.
My current major areas of research interest at UEA centre on the development of methods to rapidly detect antibiotic resistant bacteria in patient specimens. Such tests would allow the swifter optimisation of a patient’s therapy, benefitting both the individual and antibiotic stewardship – thus meeting key objectives highlighted in the Chief Medical Officer’s Annual Report for 2013. Other areas of interest are gut carriage of resistant bacteria and the relationship between in-vitro resistance and treatment outcome, Through on-going links with Public Health England I remain deeply involved in the surveillance of antibiotic resistance, the investigation of emerging resistance types and the in-vitro evaluation of new antibiotics against these organisms.
Research Keywords: Antibiotic resistance, ?-Lactamase, Carbapenem, Antibiotic development
Research Topics for PGR Supervision: Epidemiology of antibiotic resistance, Mechanisms of antibiotic resistance, Detection of antibiotic resistance
Teaching Interests
In a research career of 30 years I have lecture widely and supervised or co-supervised 15 PhD student to successful completion. I currently supervise one PhD student, working on rapid microbiological investigation of urinary tract infections and co-supervise two others, one working on the strain structure of carbapenemase-producing Pseudomonas aeruginosa in the UK and the other on gen expression in P, aeruginosa biofilms.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Philosophy, Ph.D., Medical Microbiology, University of London
… → 1983
Bachelor of Science, B.Sc., Microbiology, Heriot-Watt University
… → 1978
External positions
Member, DoH Antimicrobial Resistance Diagnostics Sub-Group
2015 → …
Steer Group Chairman, Gonococcal Resistance to Antibiotics Surveillance Programme (PHE)
2014 → …
Editorial Board Member, Korean Journal of Internal Medicine
2011 → …
Editorial Board Member, Antimicrobial Agents and Chemotherapy
2010 → …
International Advisory Board Member, Journal of Microbiology, Immunology & Infection
2010 → …
Media Expertise
- Medicine
- Covid
- Microbiology
- Antibiotic resistance
Collaborations and top research areas from the last five years
Projects
- 8 Finished
-
Development evaluation and implementation of molecular diagnostics for hospital-acquired and ventilator-associated pneumonia in diverse UK hospital settings
Livermore, D., O'Grady, J., Colles, A., High, J., Sims, E., Swart, A. M., Turner, D., Wagner, A. & Russell, C.
National Institute for Health and Care Research
1/01/16 → 30/06/23
Project: Research
-
-
Rapid, sequencing based, diagnosis of sepsis (SepsiSeq)
O'Grady, J., Livermore, D. & Wain, J.
1/04/15 → 30/09/17
Project: Research
-
Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance
Mushtaq, S., Vickers, A., Woodford, N. & Livermore, D. M., Mar 2024, In: International Journal of Antimicrobial Agents. 63, 3, 107081.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Citations (Scopus)13 Downloads (Pure) -
Regional variations in antimicrobial susceptibility of community-acquired uropathogenic Escherichia coli in India: findings of a multicentric study highlighting the importance of local antibiograms
Rizvi, M., Malhotra, S., Agarwal, J., Siddiqui, A. H., Devi, S., Poojary, A., Thakuria, B., Princess, I., Sami, H., Gupta, A., Sultan, A., Jitendranath, A., Mohan, B., Banashankari, G. S., Khan, F., Kalita, J. B., Jain, M., Singh, N. P., Gur, R., Mohapatra, S., & 27 others , Jun 2024, In: IJID Regions. 11, 100370.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Downloads (Pure) -
UK clinicians’ attitudes towards the application of molecular diagnostics to guide antibiotic use in ICU patients with pneumonias: A quantitative study
Stewart, S-J. F., Pandolfo, A. M., Moon, Z., Jani, Y., Brett, S. J., Brealey, D., Singh, S., Enne, V. I., Livermore, D. M., Gant, V., Horne, R. & INHALE Study Group, 3 Jan 2024, In: Journal of Antimicrobial Chemotherapy. 79, 1, p. 123–127 5 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile13 Downloads (Pure) -
Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli
Livermore, D. M., Mushtaq, S., Vickers, A. & Woodford, N., May 2023, In: International Journal of Antimicrobial Agents. 61, 5, 106776.Research output: Contribution to journal › Article › peer-review
Open AccessFile14 Citations (Scopus)11 Downloads (Pure) -
Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales
Mushtaq, S., Garello, P., Vickers, A., Woodford, N. & Livermore, D. M., Oct 2022, In: Journal of Antimicrobial Chemotherapy. 77, 10, p. 2772–2778 7 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Citations (Scopus)10 Downloads (Pure)
Activities
-
DoH Antimicrobial Resistance Diagnostics Sub-Group (External organisation)
David Livermore (Member)
2015 → …Activity: Membership › Committee
-
Gonococcal Resistance to Antibiotics Surveillance Programme (PHE) (External organisation)
David Livermore (Chair)
2014 → …Activity: Membership › Committee
-
CMO's working group on genomics (Science Group) (External organisation)
David Livermore (Member)
2013Activity: Membership › Network, Working Group or Professional Association
-
-
Press/Media
-
Is the mutant virus really out of control? Professor DAVID LIVERMORE argues the escalating mood of crisis is unwarranted
21/12/20
1 item of Media coverage
Press/Media: Media Coverage or Contribution
-
My manifesto to beat coronavirus crisis: Protect the elderly and vulnerable, let the rest live their lives, and throw Britain open again, writes Professor DAVID LIVERMORE
7/10/20
1 item of Media coverage
Press/Media: Media Coverage or Contribution
-
Norwich researchers play part in pneumonia test for coronavirus patients
25/04/20
1 item of Media coverage
Press/Media: Media Coverage or Contribution
-
Real-time pneumonia test for COVID-19 patients aiding faster therapy
24/04/20
1 item of Media coverage
Press/Media: UEA Press Release
-
Study: Not washing your hands after bathroom more harmful than eating raw meat
25/10/19
1 item of Media coverage
Press/Media: Media Coverage or Contribution